Agile Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
February 20 2020 - 4:14PM
Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare
company, today announced that it intends to offer and sell shares
of its common stock in an underwritten public offering. All shares
being offered are to be sold by Agile Therapeutics. Agile
Therapeutics intends to grant the underwriters a 30-day option to
purchase an additional fifteen percent of the shares of common
stock offered in the public offering. The proposed offering
is subject to market and other conditions, and there can be no
assurances as to whether or when the offering may be completed, or
as to the actual size or terms of the offering.
The joint book-running managers for the offering
are RBC Capital Markets, William Blair and Oppenheimer & Co. In
addition, H.C. Wainwright & Co., Maxim Group LLC, and Janney
Montgomery Scott are acting as co-managers.
The shares of common stock described above are
being offered by Agile Therapeutics pursuant to its shelf
registration statement on Form S-3 previously filed and declared
effective by the Securities and Exchange Commission. The
offering is being made only by means of a preliminary prospectus
supplement and the accompanying prospectus, copies of which may be
obtained, when available, from RBC Capital Markets, LLC, Attention:
Equity Capital Markets, 200 Vesey Street, New York, NY 10281, by
telephone at 877-822-4089 or by email at
equityprospectus@rbccm.com; William Blair & Company, L.L.C.,
Attention: Prospectus Department, 150 North Riverside Plaza,
Chicago, IL 60606; Telephone: (800) 621-0687 or by email at
prospectus@williamblair.com; and Oppenheimer & Co., Inc.,
Attention: Syndicate Prospectus Department, 85 Broad St., 26th
Floor, New York, NY 10004, by telephone at (212) 667-8055 or by
email at EquityProspectus@opco.com.
Before investing in the offering, you should
read in their entirety the prospectus supplement and accompanying
prospectus and the other documents that Agile Therapeutics has
filed with the Securities and Exchange Commission that are
incorporated by reference in the prospectus supplement and the
accompanying prospectus, which provide more information about Agile
Therapeutics and the offering.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy these securities, nor
shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Agile Therapeutics,
Inc.
Agile Therapeutics is a women's healthcare
company dedicated to fulfilling the unmet health needs of today’s
women. Our product candidates are designed to provide women
with contraceptive options that offer freedom from taking a daily
pill, without committing to a longer-acting method. Our
initial product, Twirla®, (levonorgestrel and ethinyl estradiol)
transdermal system is a non-daily prescription contraceptive.
Twirla is based on our proprietary transdermal patch technology,
called Skinfusion®, which is designed to allow drug delivery
through the skin. For more information, please visit the company
website at www.agiletherapeutics.com. The Company may occasionally
disseminate material, nonpublic information on the Company’s
website.
Follow Agile on Linked In and Twitter: @AgileTher.
Forward-Looking Statement
Certain information contained in this press
release includes "forward-looking statements" within the meaning of
The Private Securities Litigation Reform Act of 1995, including
statements related to our public offering. We may, in some cases,
use terms such as "predicts," "believes," "potential," "continue,"
"anticipates," "estimates," "expects," "plans," "intends," "may,"
"could," “might," "will," "should" or other words that convey
uncertainty of the future events or outcomes to identify these
forward-looking statements. Our forward-looking statements are
based on current beliefs and expectations of our management team
that involve risks, potential changes in circumstances,
assumptions, and uncertainties. Any or all of the forward-looking
statements may turn out to be wrong or be affected by inaccurate
assumptions we might make or by known or unknown risks and
uncertainties as a result of various important factors, including
the uncertainties related to market conditions and the completion
of the public offering on the anticipated terms or at all and such
other factors. For a more detailed description of the risks
and uncertainties that could cause actual results to differ from
those expressed in these forward-looking statements, as well as
risks relating to our business in general, please refer to our
prospectus supplement to be filed with the Securities and Exchange
Commission (SEC) on February 20, 2020 under the heading “Risk
Factors” and those documents incorporated by reference therein,
which includes our Annual Report on Form 10-K and our Quarterly
Reports on Form 10-Q. You are cautioned not to place undue reliance
on these forward-looking statements, which are made only as of the
date of this press release. We undertake no obligation to publicly
update such forward-looking statements to reflect subsequent events
or circumstances.
Source: Agile Therapeutics
Contact: Investor Relations (609)
683-1880
Agile Therapeutics (NASDAQ:AGRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Agile Therapeutics (NASDAQ:AGRX)
Historical Stock Chart
From Sep 2023 to Sep 2024